(Q35263056)

7 August 2017

title

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer (English)

1 reference

7 August 2017

1 reference

1 reference

1 reference

randomized experiment

1 reference

F A Raja

1

1 reference

7 August 2017

C L Griffin

2

1 reference

7 August 2017

W Qian

3

1 reference

7 August 2017

H Hirte

4

1 reference

7 August 2017

M K Parmar

5

1 reference

7 August 2017

A M Swart

6

1 reference

7 August 2017

J A Ledermann

7

1 reference

7 August 2017

language of work or name

English

0 references

publication date

30 August 2011

1 reference

British Journal of Cancer

7 August 2017

published in

1 reference

7 August 2017

volume

105

1 reference

7 August 2017

issue

7

1 reference

7 August 2017

page(s)

884-889

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2011.334

7 August 2017

uses

randomized experiment

0 references

exact match

0 references

cites work

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185949

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185949

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185949

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185949

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185949

Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones

26 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2011.334

21 January 2018

Identifiers

DOI

10.1038/BJC.2011.334

1 reference

7 August 2017

1 reference

7 August 2017

1 reference